The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats
Abstract
VEGF signaling inhibition decreases alveolar and vessel growth in the developing lung, suggesting that impaired VEGF signaling may contribute to decreased lung growth in bronchopulmonary dysplasia (BPD). Whether VEGF treatment improves lung structure in experimental models of BPD is unknown. The objective was to determine whether VEGF treatment enhances alveolarization in infant rats after hyperoxia. Two-day-old Sprague-Dawley rats were placed into hyperoxia or room air (RA) for 12 days. At 14 days, rats received daily treatment with rhVEGF-165 or saline. On day 22, rats were killed. Tissue was collected. Morphometrics was assessed by radial alveolar counts (RAC), mean linear intercepts (MLI), and skeletonization. Compared with RA controls, hyperoxia decreased RAC (6.1 ± 0.4 vs. 11.3 ± 0.4, P < 0.0001), increased MLI (59.2 ± 1.8 vs. 44.0 ± 0.8, P < 0.0001), decreased nodal point density (447 ± 14 vs. 503 ± 12, P < 0.0004), and decreased vessel density (11.7 ± 0.3 vs. 18.9 ± 0.3, P < 0.001), which persisted despite RA recovery. Compared with hyperoxic controls, rhVEGF treatment after hyperoxia increased RAC (11.8 ± 0.5, P < 0.0001), decreased MLI (42.2 ± 1.2, P < 0.0001), increased nodal point density (502 ± 7, P < 0.0005), and increased vessel density (23.2 ± 0.4, P < 0.001). Exposure of neonatal rats to hyperoxia impairs alveolarization and vessel density, which persists despite RA recovery. rhVEGF treatment during recovery enhanced vessel growth and alveolarization. We speculate that lung structure abnormalities after hyperoxia may be partly due to impaired VEGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Cited by
Thébaud, B., & Abman, S. H. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200611-1660pp · Cited by 540
Self-citationPathology of Bronchopulmonary Dysplasia
Coalson, J. J. (2006) · Seminars in Perinatology · doi:10.1053/j.semperi.2006.05.004 · Cited by 370
Metadata
- Authors
- Kunig, A. M., Balasubramaniam, V., Markham, N. E., Morgan, D., Montgomery, G., Grover, T. R., & Abman, S. H.
- Venue
- American Journal of Physiology-Lung Cellular and Molecular Physiology
- Publisher
- American Physiological Society
- Published
- 2005-10
- Volume
- 289
- Issue
- 4
- Pages
- L529-L535
- ISSN
- 1040-0605 (ISSN-L)
- 1522-1504
- OpenAlex
- W2111543200
- Cited by
- 208
- References
- 1
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. https://app.cochat.ai/papers/10.1152/ajplung.00336.2004
- The paper
- Kunig, A. M., Balasubramaniam, V., Markham, N. E., Morgan, D., Montgomery, G., Grover, T. R., & Abman, S. H. (2005). Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.00336.2004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.